HOOKIPA leverages a differentiated arenavirus platform that reprograms the immune system to target multiple therapeutic areas. The company has established strategic partnerships with Gilead Sciences for HB-400 (hepatitis B) and HB-500 (HIV) programs. However, recent asset dispositions signal a pivot toward liquidation, with immuno-oncology assets sold to NeoTrail Therapeutics in January 2026 and intention to delist from NASDAQ.
Cyborg Score Rationale
HOOKIPA faces severe strategic challenges with voluntary delisting announcement, asset sales, and company dissolution plans. The company has divested key oncology programs and partnered away its infectious disease pipeline to Gilead. Current market conditions and financial constraints appear to have forced a wind-down strategy rather than growth trajectory.
Top Insights
Major corporate restructuring: Sold immuno-oncology assets (HB-200 eseba-vec, HB-700) to NeoTrail Therapeutics (January 28, 2026)
Strategic partnership with Gilead: Transferred HB-400 and HB-500 programs; completed sale October 30, 2025 for reported $10 million consideration
Delisting trajectory: Company announced intention to voluntarily delist from NASDAQ and seek stockholder approval for dissolution and liquidation (July 2025)
Clinical milestone: Completed Phase 1b enrollment for HB-500 HIV vaccine with 30 participants across five U.S. sites (July 2024 initiation)
Named Competitors
Immuno-oncology and cancer immunotherapy — Engineered oncolytic immunotherapy platform
Therapeutic vaccine development — Synthetic vaccine platform for infectious diseases
Immunotherapy development — Nanoparticle vaccine and immunotherapy development
Recent Developments
(January 2026) Sold immuno-oncology assets to NeoTrail Therapeutics
(October 2025) Completed asset sale to Gilead Sciences (HB-400 and HB-500 programs)
(July 2025) Announced intention to voluntarily delist from NASDAQ
(January 2025) Completed enrollment of Phase 1b trial for HB-500 HIV vaccine
Open the full interactive HOOKIPA Pharma Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.